These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28550080)

  • 41. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
    Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
    PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
    Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
    J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
    Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
    Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients.
    Imtiaz R; Hawken S; McCormick BB; Leung S; Hiremath S; Zimmerman DL
    Nutrients; 2017 Feb; 9(2):. PubMed ID: 28218647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
    Jamal SA; Vandermeer B; Raggi P; Mendelssohn DC; Chatterley T; Dorgan M; Lok CE; Fitchett D; Tsuyuki RT
    Lancet; 2013 Oct; 382(9900):1268-77. PubMed ID: 23870817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
    Yin J; Yin J; Lian R; Li P; Zheng J
    BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
    Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calcium-enriched bread for treatment of uremic hyperphosphatemia.
    Babarykin D; Adamsone I; Amerika D; Spudass A; Moisejev V; Berzina N; Michule L; Rozental R
    J Ren Nutr; 2004 Jul; 14(3):149-56. PubMed ID: 15232793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mild hyperphosphatemia and mortality in hemodialysis patients.
    Rodriguez-Benot A; Martin-Malo A; Alvarez-Lara MA; Rodriguez M; Aljama P
    Am J Kidney Dis; 2005 Jul; 46(1):68-77. PubMed ID: 15983959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
    Chen JB; Chiang SS; Chen HC; Obayashi S; Nagasawa M; Hexham JM; Balfour A; Junge G; Akiba T; Fukagawa M
    Nephrology (Carlton); 2011 Nov; 16(8):743-50. PubMed ID: 21854503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
    Di Iorio B; Bellasi A; Russo D;
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study.
    Leung S; McCormick B; Wagner J; Biyani M; Lavoie S; Imtiaz R; Zimmerman D
    BMC Nephrol; 2015 Dec; 16():205. PubMed ID: 26645271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
    Galassi A; Cupisti A; Santoro A; Cozzolino M
    J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
    Chang YM; Tsai SC; Shiao CC; Liou HH; Yang CL; Tung NY; Hsu KS; Chen IL; Liu MC; Kao JL; Jhen RN; Huang YT
    Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial.
    Walsh M; Manns BJ; Klarenbach S; Tonelli M; Hemmelgarn B; Culleton B
    Hemodial Int; 2010 Apr; 14(2):174-81. PubMed ID: 20041960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.